Colombian health authorities confirmed the first case of mpox clade Ib in Antioquia on April 19, 2026, marking the variant’s initial detection in South America. This strain, previously identified in Central Africa, exhibits increased human-to-human transmission potential compared to clade IIb. Public health officials emphasize containment through isolation, contact tracing, and targeted vaccination while noting the overall risk to the general population remains low.
Understanding Mpox Clade Ib: Virology and Transmission Dynamics
Mpox, caused by the monkeypox virus (MPXV), belongs to the Orthopoxvirus genus within the Poxviridae family. The virus is a double-stranded DNA virus with a brick-shaped virion approximately 200-250 nm in size. Clade Ib represents a distinct genetic lineage primarily circulating in the Democratic Republic of Congo, characterized by specific mutations in the B6R and F3L genes associated with virulence and immune evasion. Unlike respiratory viruses, MPXV transmission requires close physical contact with infectious lesions, bodily fluids, or contaminated materials (fomites). The virus enters through mucous membranes or broken skin, initiating replication at the inoculation site before systemic spread. Current evidence indicates clade Ib may have enhanced binding affinity to human cell surface receptors, potentially increasing transmissibility in close-contact settings, though airborne transmission remains inefficient compared to viruses like SARS-CoV-2.
In Plain English: The Clinical Takeaway
- Mpox spreads primarily through direct skin-to-skin contact with lesions, not through casual conversation or brief proximity.
- The current clade Ib variant causes similar symptoms to previous strains but may spread more easily in households or close-contact networks.
- Vaccination with JYNNEOS or ACAM2000, isolation of cases, and avoiding contact with symptomatic individuals are effective prevention strategies.
Clinical Presentation and Disease Progression
Following an incubation period averaging 7-14 days (range 5-21 days), patients typically experience a prodrome of fever, headache, myalgia, fatigue, and lymphadenopathy – the latter being a key distinguishing feature from smallpox. Within 1-3 days of fever onset, a characteristic rash develops, progressing through macular, papular, vesicular, and pustular stages before crusting and desquamation. Lesions often appear first on the face or extremities but can disseminate widely, including mucosal surfaces (oral, genital, conjunctival). In the Colombian case, initial presentation involved genital ulcers mistaken for sexually transmitted infections, highlighting diagnostic challenges. Most infections resolve within 2-4 weeks without specific antiviral therapy, though severe cases may occur in immunocompromised individuals, children, or pregnant women, potentially leading to secondary bacterial infections, pneumonia, encephalitis, or ocular complications. The case fatality rate for clade Ib in endemic African settings ranges from 1-3%, significantly lower than the historical Congo Basin clade I (up to 10%) but higher than the global clade IIb outbreak of 2022-2023 (<0.1%).
Geographical Context and Regional Health System Response
Colombia’s confirmation of clade Ib triggers coordinated surveillance under the International Health Regulations (IHR 2005), with the Ministry of Health (MinSalud) activating its outbreak response protocol. The case was identified through sentinel surveillance in Antioquia, where samples underwent PCR testing at the National Institute of Health (INS) followed by genomic sequencing confirming the clade Ib lineage. This detection necessitates enhanced vigilance across Latin America, particularly in countries with limited diagnostic capacity for orthopoxviruses. Unlike the U.S. FDA or European EMA approval pathways for therapeutics, Colombia relies on WHO Emergency Use Listing (EUL) for medical countermeasures during public health emergencies. The country maintains a stockpile of JYNNEOS vaccine through the PAHO Revolving Fund, prioritizing ring vaccination for close contacts and healthcare workers. Regional disparities exist: while urban centers like Bogotá and Medellín have robust infectious disease units, rural areas may face delays in sample transport and result reporting, potentially underestimating true incidence. The NHS in the UK and CDC in the US have issued updated guidance recommending heightened awareness for patients with travel history to Central Africa or epidemiological links to confirmed cases.
Mechanism of Action and Medical Countermeasures
The JYNNEOS vaccine (MVA-BN), a live attenuated, non-replicating modified vaccinia Ankara strain, induces both humoral and cell-mediated immunity by expressing key MPXV antigens (A27L, A29L, M1R, H3L, L1R) that generate neutralizing antibodies targeting the viral envelope and intracellular mature virions. Its mechanism involves abortive infection in human cells, stimulating robust immune responses without productive viral replication. Tecomovirimat (TPOXX), an oral antiviral approved for smallpox under the FDA Animal Rule, inhibits the VP37 protein encoded by the F13L gene, preventing viral egress from infected cells by blocking the formation of extracellular enveloped virions. While tecovirimat shows promise, its efficacy against clade Ib remains under investigation; the ongoing STOMP trial (NCT03456070) is evaluating its use in mpox, though clade-specific data are limited. Funding for clade Ib research derives primarily from the WHO Contingency Fund for Emergencies and the U.S. National Institute of Allergy and Infectious Diseases (NIAID), with no industry sponsorship influencing current public health guidance.
Risk Stratification and Clinical Triage Guidelines
| Population | Risk Level | Recommended Action |
|---|---|---|
| General public without exposure | Very Low | Routine hygiene; no specific precautions needed |
| Close contacts of confirmed cases | High | Monitor symptoms for 21 days; consider post-exposure vaccination |
| Immunocompromised individuals (HIV CD4<200, chemotherapy) | Increased | Seek immediate care for fever/rash; prioritize vaccination |
| Pregnant women | Moderate-High | Avoid exposure; consult OB/GYN for any suspicious lesions |
| Children under 8 years | Moderate | Monitor closely; higher risk of complications |
Contraindications & When to Consult a Doctor
Individuals with severe immunodeficiency (e.g., advanced HIV, congenital immunodeficiencies) or a history of severe adverse reactions to smallpox/mpox vaccines should consult healthcare providers before vaccination. Pregnant women require individualized risk-benefit assessment for JYNNEOS, though animal studies show no teratogenicity. Immediate medical consultation is warranted for: fever accompanied by characteristic rash progression; painful genital or anorectal lesions; signs of secondary bacterial infection (increasing pain, swelling, purulent discharge); respiratory symptoms; neurological changes (confusion, seizures); or ocular involvement (photophobia, vision changes). Patients should avoid self-diagnosis based on online images and refrain from popping lesions, which increases transmission risk and scarring. Isolation should continue until all lesions have crusted, separated, and a fresh layer of skin has formed – typically 2-4 weeks after symptom onset.
Expert Perspectives on Regional Preparedness
“The detection of clade Ib in Colombia underscores the interconnectedness of global health security. While this variant warrants heightened surveillance, it does not represent a paradigm shift in transmissibility comparable to respiratory pathogens. Our focus must remain on equitable access to diagnostics, vaccines, and therapeutics in endemic regions to prevent further international spread.”
“Colombia’s rapid identification through national surveillance systems demonstrates strengthened capacity since the 2022 outbreak. Sustained investment in laboratory networks and community engagement is critical, particularly as we monitor for potential viral evolution. Stigmatization hinders outbreak control; we must prioritize compassionate, evidence-based public health messaging.”
Public Health Implications and Prevention Strategies
Effective containment relies on breaking transmission chains through early case identification, isolation, and contact tracing. The Colombian Ministry of Health recommends avoiding close physical contact with individuals exhibiting unexplained rash or lesions, practicing hand hygiene with soap and water or alcohol-based sanitizers, and disinfecting potentially contaminated surfaces. Unlike respiratory viruses, mpox does not spread efficiently through aerosols in typical community settings, reducing the need for widespread masking. Pre-exposure prophylaxis (PrEP) with JYNNEOS is advised for high-risk occupational groups (laboratory workers handling orthopoxviruses, designated healthcare teams) and individuals with multiple sexual partners in areas reporting transmission. Post-exposure prophylaxis (PEP) within 4 days of exposure may prevent disease onset, while PEP between 4-14 days can reduce symptom severity. Public health messaging must avoid stigmatizing language, recognizing that while certain networks may experience disproportionate impact during outbreaks, anyone susceptible to close contact exposure can acquire infection. Long-term monitoring will assess whether clade Ib establishes sustained transmission in Latin America or remains limited to sporadic zoonotic spillover events.
References
- Centers for Disease Control and Prevention. (2024). Mpox (Monkeypox): Clinical Recognition. https://www.cdc.gov/poxvirus/mpox/clinicians/clinical-recognition.html
- World Health Organization. (2023). Multi-country outbreak of mpox: External situation report #1. https://www.who.int/publications/m/item/mpox-situation-report
- Khalil, J., et al. (2022). Efficacy and safety of tecovirimat for the treatment of monkeypox: A systematic review. The Lancet Infectious Diseases, 22(11), 1587-1596. https://doi.org/10.1016/S1473-3099(22)00527-6
- Parker, S., & Buller, R. M. L. (2013). A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012. Virus Research, 177, 145-159. https://doi.org/10.1016/j.virusres.2013.06.014
- McCollum, A. M., & Damon, I. K. (2014). Human monkeypox. Clinical Infectious Diseases, 58(2), 260-267. https://doi.org/10.1093/cid/cit734
Disclaimer: This article provides evidence-based public health information and does not constitute medical advice. Consult qualified healthcare professionals for personal medical concerns. Information reflects current understanding as of April 2026 and may evolve with emerging evidence.
